Envestnet Portfolio Solutions
NBIX icon

Envestnet Portfolio Solutions’s Neurocrine Biosciences NBIX Stock Holding History

Envestnet Portfolio Solutions’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$496K Buy
2,942
+590
+25% +$87.5K ﹤0.01% 993
2026
Q1 		$310K Sell
2,352
-1,340
-36% -$178K ﹤0.01% 1103
2025
Q4 		$524K Sell
3,692
-9
-0.2% -$1.3K ﹤0.01% 1039
2025
Q3 		$520K Buy
3,701
+428
+13% +$58K ﹤0.01% 1016
2025
Q2 		$411K Buy
3,273
+645
+25% +$74K ﹤0.01% 1188
2025
Q1 		$291K Sell
2,628
-240
-8% -$30.4K ﹤0.01% 1302
2024
Q4 		$391K Buy
2,868
+278
+11% +$34.4K ﹤0.01% 1356
2024
Q3 		$298K Sell
2,590
-120
-4% -$16.5K ﹤0.01% 1456
2024
Q2 		$373K Buy
2,710
+168
+7% +$23K ﹤0.01% 1260
2024
Q1 		$351K Buy
2,542
+12
+0.5% +$1.64K ﹤0.01% 1277
2023
Q4 		$333K Buy
2,530
+78
+3% +$8.98K ﹤0.01% 1237
2023
Q3 		$276K Buy
+2,452
New +$258K ﹤0.01% 1269

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Envestnet Portfolio Solutions's NBIX Position: Q2 2026 in Review

Envestnet Portfolio Solutions increased its Neurocrine Biosciences (NBIX) stake by 25% in Q2 2026, buying an estimated $87.5K and bringing the position to 2,942 shares worth $496K. The position accounts for ﹤0.01% of the portfolio, ranked #993.

Envestnet Portfolio Solutions first reported a position in NBIX in Q3 2023 and has held it in 12 quarters since. The position peaked at $524K in Q4 2025. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Envestnet Portfolio Solutions held 2,942 shares of Neurocrine Biosciences worth $496K as of Q2 2026.
  • Envestnet Portfolio Solutions bought 590 Neurocrine Biosciences shares in Q2 2026, an estimated $87.5K.
  • Neurocrine Biosciences made up ﹤0.01% of Envestnet Portfolio Solutions's portfolio in Q2 2026, its #993 holding.
  • Envestnet Portfolio Solutions first reported a position in Neurocrine Biosciences in Q3 2023 and has held it in 12 quarters since.
  • Envestnet Portfolio Solutions's Neurocrine Biosciences position peaked at $524K in Q4 2025.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Envestnet Portfolio Solutions's 13F filing for Q2 2026, filed 20 Jul 2026.